Changes in osteoporosis therapy in postmenopausal women from the RAC‑OST‑POL study: a 10‑year follow‑up
Wojciech Pluskiewicz1, Piotr Adamczyk2, Bogna Drozdzowska3
1Department and Clinic of Internal Diseases, Diabetology, and Nephrology, Metabolic Bone Diseases Unit, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, Katowice, Poland. wpluskiewicz@sum.edu.pl
Introduction:
Therapeutic regimens for osteoporosis are the key elements in the management of osteoporotic patients.
Objective:
The aim of the study was to present data on changes in osteoporosis therapy in women during a 10‑year follow‑up.
Patients And Methods:
We analyzed a population‑based sample recruited in the RAC‑OST‑POL study. At baseline, the cohort included 978 women, of whom 541 remained in the follow‑up. Mean (SD) age of the patients was 74.7 (6.6) years.
Results:
The number of untreated women and those on alendronate decreased, while the number of patients receiving other forms of the antiresorptive therapy or calcium / vitamin D supplementation increased during the study. The percentage of untreated women in the rural areas and the urban areas was, respectively, 85% and 74.1% at baseline, and 74.3% and 63.3% at the end of the follow‑up. The percentage of untreated women decreased significantly, both in rural and urban cohorts. It was accompanied by a significant increase in calcium / vitamin D supplementation in both subgroups. Regarding the antiresorptive therapy, there was a significant increase in the frequency of its use only in the rural cohort. The use of therapeutic strategies was determined by the level of education. The frequency of calcium and / or vitamin D supplementation increased significantly in all education-related categories during the follow‑up.
Conclusion:
Changes in the therapy of postmenopausal women with osteoporosis, observed in a 10‑year follow‑up of the RAC‑OST‑POL study, indicated that the level of care did not improve in this group of patients.
Related Concept Videos
01:40Bone Remodeling
01:29Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
01:31Osteoclasts in Bone Remodeling
01:25Role of Vitamins in Maintaining Bone Health
Vitamin A
Vitamin A is involved in the process of bone remodeling. Retinoic acid, the active metabolite of Vitamin A, has nuclear receptors in osteoblasts and osteoclasts, which are involved in bone remodeling.
Vitamin B12
Vitamin B12 acts as a cofactor during the formation of osteoblast-related proteins, such as osteocalcin. Vitamin B12 plays a role...
01:17Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...